Version 1
: Received: 15 January 2019 / Approved: 16 January 2019 / Online: 16 January 2019 (07:54:33 CET)
How to cite:
Goh, T.S.; Ha, M.; Lee, J.S.; Jeong, D.C.; Jung, E.S.; Han, M.; Kim, Y.H.; Oh, S. Prognostic Significance of EIF4G1 in Patients with Pancreatic Ductal Adenocarcinoma. Preprints2019, 2019010155. https://doi.org/10.20944/preprints201901.0155.v1
Goh, T.S.; Ha, M.; Lee, J.S.; Jeong, D.C.; Jung, E.S.; Han, M.; Kim, Y.H.; Oh, S. Prognostic Significance of EIF4G1 in Patients with Pancreatic Ductal Adenocarcinoma . Preprints 2019, 2019010155. https://doi.org/10.20944/preprints201901.0155.v1
Goh, T.S.; Ha, M.; Lee, J.S.; Jeong, D.C.; Jung, E.S.; Han, M.; Kim, Y.H.; Oh, S. Prognostic Significance of EIF4G1 in Patients with Pancreatic Ductal Adenocarcinoma. Preprints2019, 2019010155. https://doi.org/10.20944/preprints201901.0155.v1
APA Style
Goh, T.S., Ha, M., Lee, J.S., Jeong, D.C., Jung, E.S., Han, M., Kim, Y.H., & Oh, S. (2019). Prognostic Significance of EIF4G1 in Patients with Pancreatic Ductal Adenocarcinoma<strong> </strong>. Preprints. https://doi.org/10.20944/preprints201901.0155.v1
Chicago/Turabian Style
Goh, T.S., Yun Hak Kim and Sae-Ock Oh. 2019 "Prognostic Significance of EIF4G1 in Patients with Pancreatic Ductal Adenocarcinoma<strong> </strong>" Preprints. https://doi.org/10.20944/preprints201901.0155.v1
Abstract
Background: The advances of genomics have greatly improved the survival rate cancer patients. However, due to genetic heterogeneity, pancreatic ductal adenocarcinoma (PDAC) is still difficult to diagnose early and the survival rate is extremely low. Therefore, we identified biomarkers that predict the prognosis of PDAC patients by using independent cohort data. Methods: To develop a novel prognostic biomarker, we used gene expression and clinical data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). In Kaplan-Meier survival curve using median values of genes as cut off, the only statistically significant gene in the three cohorts was EIF4G1. We analyzed prognostic significance of EIF4G1 using the time-dependent area under the curve (AUC) of the Uno's C-index, the AUC value of the receiver operating characteristics (ROC) at 3 years, and multivariate cox analysis. Also, we compare EIF4G1 levels between tumor and matched non-tumor. Results: EIF4G1 is the only prognostic gene patients with PDAC which was selected by Kaplan-Meier survival analysis. Kaplan-Meier survival analysis showed that high expression of EIF4G1 was associated with poor prognosis of PDAC with good discriminative ability in 3 independent cohorts. Risk stratifying ability of EIF4G1 was demonstrated by analyzing C-indices and AUC values. Multivariate cox regression analysis confirmed its prognostic significance. EIF4G1 expression was significantly higher in the PDAC tissues than in the matched normal tissues. Conclusions: Herein, the novel prognostic biomarker EIF4G1 could be used as prognostic maker for PDAC and determining suitable treatment options.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
*
,
*
